Podcast by Dr. Cush
Listeners of Rheumnow Podcast that love the show mention: great, thank, dr cush.
The Rheumnow Podcast is an invaluable resource for anyone in the field of rheumatology or those with an interest in staying up to date with the latest research and news in this area. Hosted by Dr. Cush and his dedicated team, this podcast offers a concise and informative overview of important developments in the field on a weekly basis.
One of the best aspects of The Rheumnow Podcast is its ability to condense complex information into easily digestible segments. Dr. Cush's presentation style is engaging and clear, making it easy to follow even for those without an extensive background in rheumatology. The podcast covers a wide range of topics, including clinical pearls, conference reviews, and updates on new research findings. This comprehensive approach ensures that listeners are kept well-informed about the latest knowledge in the field.
Another positive aspect of this podcast is the dedication and effort put into its production. Dr. Cush and his team clearly invest a significant amount of time and energy into gathering the most relevant and important content for each episode. This commitment to providing high-quality educational material is evident in every episode, making it an invaluable resource for both practicing rheumatologists and those looking to expand their knowledge.
While there are many positive aspects to The Rheumnow Podcast, one potential drawback is its specialization in rheumatology. As mentioned by some reviewers, the content can be highly specialized and may not be as accessible or relevant for individuals outside of this field. However, given that this podcast is primarily targeted towards rheumatologists or those with a specific interest in rheumatology, it serves its purpose well.
In conclusion, The Rheumnow Podcast is an exceptional resource for staying updated with the latest knowledge in rheumatology. Dr. Cush's engaging presentation style coupled with his team's dedication to providing high-quality content make this podcast a must-listen for anyone involved in this field. Whether you're a practicing rheumatologist or simply interested in learning more about rheumatology, this podcast offers valuable insights and clinical pearls that can enhance patient care and keep you well-informed.
Dr. Jack Cush reviews the news and recent journal reports on RheumNow.com
Dr. Christina Charles-Schoeman and Dr. Manish Jain are back to discuss treatment considerations after TNFi failure in RA. Join them as they review the latest data from SELECT-SWITCH, including post hoc results in primary and secondary nonresponders presented at EULAR 2026. Learn how those findings impact their clinical decision-making. Sponsored by AbbVie Medical Affairs + Health Impact
Dr. Jack Cush Obesity & Gout Dr. Tony Merriman Genome-Wide Association Studies in Gout Dr. Lisa Stamp Gout Management in Patients with Chronic Kidney Disease Dr. Mark Fisher Gout & Mortality
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com
Dr. Sheila Reyes: QD Clinic: The Highs and Lows of a Woman with Gout Dr. Jack Cush QD319 A Watched Tophus Never Resolves Dr. Eric Dein QD316: Addressing Severe Gout Flares Dr. Janet Pope QD Clinic: RA Mimics — Two Cases That Turned Out to Be Gout
The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, CTD skin disorders. dermatology drugs, biologics, andJAK inhibitors - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. Show Notes: - 20 yr. Tx trends in 6583 #SSc pts. 2005 to 2025 endothelin receptor antagonists & prostanoids/prostacyclins from 3% to 28%. CCB & PDE-5 inh stable. CTX shifted to mycophenolate, RTX, & nintedanib. Steriods decr from 50% to 18% https://t.co/nrm1Ov285f https://t.co/ftLn3bGH72 Systemic sclerosis metanalysis of 31 studies (32,134 pts) shows malignancy risk signif increased (SIR 1.66; CI 1.32 - 2.08). Highest: esophageal, liver, cervical, lung, & Heme (SIR 3.35 - 13.95). 7.4 yr mean from SSc to CA dx. https://t.co/IhxvfkMqkf RZV (Shingrix) response in 76 immunosuppressed SSc & 304 controls (CG) recv two RZV doses. High seroconversion seen in SSc but signif lower than CG (92.6% vs 99.7%, P 0.001), w/ lower concentration but comparable CMI, lower AE (74% vs 86%) https://t.co/ALlnVEZIAt https://t.co/kYYy2JIo2J Raynauds: Using the Clinical Practice Research Datalink Aurum (PCP) database (1998 - 2023) the prevalence of Raynaud's 894/100 000, or 158449 cases in 2023. More in elderly & females, less in blacks. Incidence rate 46/100K https://buff.ly/TLjMy21 Guidelines to Spot Cancer in High Risk Dermatomyositis Psoriatic Arthritis: EULAR 2026
New, Advanced Therapies in Gout explores the rapidly evolving therapeutic landscape beyond conventional urate-lowering therapy. Join our expert panel as they discuss emerging approaches—including cytokine inhibition, uricase therapies, NLRP3 and URAT-1 inhibitors, and the potential role of GLP-1 receptor agonists and SGLT2 inhibitors—while addressing which patients are most likely to benefit, how these agents fit into current treatment algorithms, and whether novel mechanisms of action have the potential to transform gout management. Panelists: Dr. Herbert Baraf Dr. Ken Saag Dr. Naomi Schlesinger Dr. Jack Cush (moderator)
Dr. Robert Terkeltaub 3 New Things it Pays to Know About Gout Pathobiology Dr. Nicola Dalbeth Outcomes of Tophaceous Gout Dr. Ted Mikuls Subclinical Inflammation in Intercritical Gout Dr. Michael Pillinger Gout and Cardiovascular Disease: What's the Risk? What's the Connection?
Dr. John Fitzgerald Gout & Metabolic syndrome Dr. Karon Jatuworpruk Predicting and managing gout flares in hospitalised patients Dr. Richard Conway Bespoke Telehealth in Gout: A Missed Opportunity
Dr. Robert Terkeltaub Four things you need to know about allopurinol hypersensitivity syndrome Dr. Angelo Gaffo Challenges in Gout Diagnosis Dr. Janet Pope Tips for safe use of allopurinol in patients with gout
Dr Janet Pope: QD Clinic: Can RA and Gout Manifest Simultaneously? Dr. Mrinalini Dey QD312: Gout, Sepsis… or Both? Daric Mueller, PA-C QD315: Pegloticase Immunomodulation: What's on the Menu? Dr. Richard Conway: QD313: Don't Presume on IL-1 in Gout
Dr. Jack Cush reviews the news, journal reports from the past week on RheumNow.com
Upgrading & Maximizing the Classics (Colchicine, Allopurinol, etc.) examines how to optimize the use of time-tested gout therapies in today's increasingly complex patients. Through practical case discussions, our expert faculty will address colchicine safety and dosing in chronic kidney disease, selecting first-line therapy for acute flares, initiating and titrating urate-lowering therapy, improving treatment adherence, and navigating challenging scenarios such as gout management in patients with CKD and cardiovascular disease. Panelist: Dr. Angelo Gaffo Dr. Lisa Stamp Dr. Michael Pillinger Dr. Ted Mikuls Moderator: Dr. Jack Cush
Dr. Jack Cush reviews the news, journal articles and Gout features from this past week on RheumNow.com
This webinar explores the evolving role of imaging in the diagnosis and management of gout. Our expert panel will discuss when and how to use ultrasound, dual-energy CT (DECT), crystal identification, and conventional radiography, while addressing practical questions such as the role of imaging in diagnostic uncertainty, serial disease monitoring, and whether ultrasound is changing the need for synovial fluid analysis in everyday practice. Panelists: Dr. Nicola Dalbeth Dr. John Fitzgerald Dr. Sarah Tedeschi Dr. Jack Cush (moderator)
QD307: Senior Year Gout https://youtu.be/_TGgcdQsfic QD308: Allopurinol for All Gout? Not Quite https://youtu.be/JAwUb-hqeFs QD309: Cellulitis Paradoxes https://youtu.be/j3feySk5wQo QD310: Gout: Is it the Journey or the Destination? https://youtu.be/1J-ZrbaGsD8 QD311: When There's Doubt in Gout https://youtu.be/DpAevfq7Oo0
Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week. July is Gout: More than Flares month. Visit https://rheumnow.com/campaign/gout-campaign-july-2026 for all of our coverage throughout July.
Gout Journal Club will examine two influential publications: 1. "Treat-to-Target Urate-Lowering Treatment and Cardiovascular Outcomes in Patients with Gout" (Cipolletta et al., JAMA Internal Medicine, 2026) and 2. "Target Serum Urate Achievement and Chronic Kidney Disease Progression in Patients With Gout and Kidney Disease"(Wang et al., JAMA Internal Medicine, 2025). Together, these studies provide new evidence supporting treat-to-target urate-lowering strategies and their potential impact on cardiovascular and renal outcomes. Panelists: Abhishek Abhishek, MD, PhD, MBBS, FRCP Zeqin Wen, MD Jie Wei, PhD Jack Cush, MD (moderator) Beyond reviewing the evidence, our expert panel will tackle the practical questions rheumatologists face every day.
In August, Dr. Christina Charles-Schoeman and Dr. Manish Jain will return with a new episode exploring the latest clinical data on RA treatment after TNFi failure. Before that episode drops, revisit their 2025 conversation on disease control, real-world data, and guidelines that inform clinical decision-making after TNFi failure. Sponsored by AbbVie Medical Affairs + Health Impact.
Dr. Jack Cush lectures on giving a great presentation; based on 40 years of lecturing in Rheumatology.
Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Updates on tofacitinib, CAR-T therapy and AI.
The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. Show Notes: - Breckenridge Pharmaceutical received FDA approval for their generic version of tofacitinib on 6/4/26. 5 mg and 10 mg tablets are now available in the U.S. market, for both adult and pediatric use. Tofacitinib Tablets are manufactured in Martorelles, Spain. https://t.co/oAh0KQSFgs - TB Infection or reactivation is Psoriasis or Psoriatic Arthritis pts taking IL-23 inhibitors is rare, rare. Literature review showed 34 studies of IL-23i in PsO had no new TB, but 1 case of LTBI reactivation. In 8 IL-23i PsA studies there were NO new TB or LTBI reactivations https://t.co/NFIap7DSOr - BE BOLD: Bimekizumab Beats Risankizumab (LB0001) –H2H trial bimekizumab vs risankizumab in PsA for 24 weeks. At week 16; BKZ better than RZB, p=0.0058). This advantage was maintained out to week 24 (55% vs 44%; p 0.0001). - RA-BRIDGE and RA-BRANCH: FDA mandated study of the risk of venous thromboembolic events (VTE) taking baricitinib (BARI) or TNF inhibitors. The incidence rate was 0.79/100 PY for BARI combined versus 0.51/100 PY for TNFi. The hazard ratio was 1.606 (95% CI 0.969–2.660), with the upper CI exceeding the pre-specified NI margin of 1.8. Baricitinib (neither dose) was associated with a higher risk of MACE (HR 1.06), all-cause mortality (HR 0.97), arterial thromboembolism (HR 1.27), or opportunistic infections (HR 1.25). - Probiotics in Psoriatic Arthritis. (POS0290) 66 PsA patients randomized to receive either placebo or probiotic containing lactobacillus and bifidobacterium strains for 12 weeks. This trial proves no significant effect with oral probiotic supplementation in PsA. - CLE and smoking. Smoking reduces efficacy of antimalarials & worsens dz activity & damage. Advocate for smoking cessation! @Rheumnow #EULAR2026 https://t.co/pEWLJAkBAJ - Risk of Psoriasis is increased 19% by long-term exposure to Particulate Matter (PM2.5 & PM10; adjHR 1.19), while short-term exposure increases risk of psoriasis exacerbation (adjusted OR 1.03). Stronger in younger, urban, lower SES, ever-smokers, & comorbid allergies https://t.co/pd6S13RG1B
Dr. Jack Cush reviews the news, journal reports and best ways to review EULAR 2026.
Drs. Jack Cush & Arthur Kavanaugh, two of rheumatology's most trusted voices, provide a breakdown of the latest breakthroughs and hottest topics in rheumatology from the EULAR 2026 meeting in London.
Join Drs. Bella Mehta, Jack Cush, Janet Pope, and Jon Kay for a focused conversation on the latest in rheumatoid arthritis care from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what's shaping RA practice right now.
Join Drs. Jack Cush, Alfred Kim, Janet Pope, and Yuz Yusof for a focused conversation on the latest in CAR-T from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what's shaping CAR-T practice right now.
Join Drs. Jack Cush, Peter Nash, Antoni Chan, and Nelly Ziade for an expert discussion on the most important psoriatic arthritis developments emerging from EULAR 2026. This focused conversation explores new clinical data, evolving treatment strategies, and practical approaches to managing PsA in everyday practice. From advances in biologic and targeted therapies to ongoing challenges in diagnosis, disease monitoring, and patient care, the panel shares key insights and take-home messages that every rheumatology clinician should know. Tune in for expert perspectives, clinical pearls, and a comprehensive look at what's shaping the future of psoriatic arthritis management.
2026 EULAR Preview Beyond BMI: Altered Body Composition in Rheumatoid Arthritis CAR-T For Rheumatoid Arthritis This Is a Woman's World: Women's Health in Rheumatic Disease Low dose Blinatumomab: Many Relapse with an Unexpected Surprise Doctor's Orders or Patient's Choice: BACH study findings Another Way to Leverage NK Cells to Kill B Cells, This Time Without CARs Digital Patient Education in RA Making Methotrexate More Effective Are we failing in the treatment of RA-ILD? Using AI to Predict Progression to RA Treat to Target Works in Elderly Onset RA RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk Improving Referrals for Inflammatory Arthritis Combination Therapy: Off the Shelf Allogenic NK and Rituximab in Rheumatic Disease
2026 EULAR Preview Imaging in Subclinical Psoriatic Arthritis Dietary Interventions in PsA This Is a Woman's World: Women's Health in Rheumatic Disease Impact of Synovial Biopsy-Driven Therapeutic Stratification in PsA Can We Stop PsA Before it Starts? BE BOLD: Going Where No PsA Trial Has Gone Before BMI Outranks Treatment in PsA Outcomes? Debate: Combination Therapies for Inflammatory Arthritis? Combination Biologics in PsA: MRI Findings from AFFINITY Combination Therapy in SpA The Case for Dual Pathway Blockade in Refractory PsA The AFFINITY Study: Combination Treatment in PsA PsA Potpourri: Probiotics & Head-to-Head Data Transition from Psoriasis to Psoriatic Arthritis MACE and Safety Profile of bDMARDs/JAKis in axSpA and PsA Guselkumab Delivers Across the PsA Disease Spectrum: APEX Trial
2026 EULAR Preview CAR-T For Rheumatoid Arthritis What Happens when CAR-T Fails Managing Disease Recurrence Management of Relapses After CAR-T Therapy in SLE, SSc and IIM How Many CAR-Ts Do We Need to Test Drive?
Guselkumab Delivers Across the PsA Disease Spectrum: APEX Trial RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk Improving Referrals for Inflammatory Arthritis" Combination Therapy: Off the Shelf Allogenic NK and Rituximab in Rheumatic Disease
Are we failing in the treatment of RA-ILD? Using AI to Predict Progression to RA Treat to Target Works in Elderly Onset RA
MACE and Safety Profile of bDMARDs/JAKis in axSpA and PsA How Many CAR-Ts Do We Need to Test Drive? Making Methotrexate More Effective
Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof for a lively discussion of the top presentations, breakthrough science, and clinical pearls from Day 4 of the EULAR 2026 Congress. Abstracts discussed included: LB001 LB002 LB003 LB005 LB007 LB009 RA Plenary POS1350
Debate: Combination Therapies for Inflammatory Arthritis? Combination Biologics in PsA: MRI Findings from AFFINITY Combination Therapy in SpA Digital Patient Education in RA The Case for Dual Pathway Blockade in Refractory PsA The AFFINITY Study: Combination Treatment in PsA PsA Potpourri: Probiotics & Head-to-Head Data Transition from Psoriasis to Psoriatic Arthritis
Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion of the top presentations, breakthrough science, and clinical pearls from Days 3 of the EULAR 2026 Congress. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288
BE BOLD: Going Where No PsA Trial Has Gone Before BMI Outranks Treatment in PsA Outcomes? What Happens when CAR-T Fails Managing Disease Recurrence Management of Relapses After CAR-T Therapy in SLE, SSc and IIM Doctor's Orders or Patient's Choice: BACH study findings Another Way to Leverage NK Cells to Kill B Cells, This Time Without CARs
Low dose Blinatumomab: Many Relapse with an Unexpected Surprise Can We Stop PsA Before it Starts? Impact of Synovial Biopsy-Driven Therapeutic Stratification in PsA
Join Dr. Jack Cush and RheumNow.com faculty for a lively discussion of the top presentations, breakthrough science, and clinical pearls from Days 1 & 2 of the EULAR 2026 Congress. Abstracts discussed included: OP0177 OP0244 OP001 OP008 OP0205 OP018 OP0204 POS0788
Imaging in Subclinical Psoriatic Arthritis CAR-T For Rheumatoid Arthritis This Is a Woman's World: Women's Health in Rheumatic Disease Dietary Interventions in PsA
2026 EULAR Preview - Dr. Jack Cush ‘Strong' Treatment Predictions in Inflammatory Myositis - Dr. Janet Pope Beyond BMI: Altered Body Composition in Rheumatoid Arthritis - Dr Mrinalini Dey Why PROMS Matter in the Care of People with Lupus - Dr. Mrinalini Dey
Dr. Jack Cush reviews the news, journal articles and missed quiz question.
Dr. Jack Cush talks of birthdays, Quizes and journal articles this week on the podcast.
Dr. Jack Cush discusses his favorite journal articles from the past week on RheumNow.com.
Dr Jack Cush reviews the news and journal reports from last weekon rheumnow.com
Dr. Jack Cush lectures on giving a great presentation; based on 40 years of lecturing in Rheumatology.
The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. Show Notes: Chinese target emulation trial of MDA-5+, dermatomyositis w/ ILD. 106 Rx w/ UPA & 328 w/ TOFA. 6-month lung transplantation-free survival 72% vs 67% (UPA v TOFA). UPA non-inferior to TOFA in MDA5+DM-ILD https://t.co/BBAfbM06AM In 2025 DTC TV ad spending by top 10 incr to $2.67 billion (up from $2.1 B). Rheum Drugs in top 3: 1. Skyrizi $440 million 2. Tremfya $431 M 3. Rinvoq $376 M https://t.co/EsWgUqUy9Z 2. Dermatology Salaries 2025 – Dermatology is top 10 at $448K according to Medscape; expected to go down -1% in 2026; derms made up 2% of survey group 37K MDs 3. Itch is common in Scleroderma (SSc) and not related to Dz duration. Study of 2173 Pts (~20K itch assessments), 87 F; mean age 55 yrs; 40% w/ diffuse SSc. Itch (moderate 4/10) seen in ~35% at all times https://t.co/QnT8d0xA5Z 4. Asia-Pacific Lupus study of Mucocutaneous activity (MC-A) in 4102 SLE pts. 36% had MC-A (rash 1055; alopecia 731; m ulcers 352); 15% persistently. MC-A assoc w/ W, smoking, +serologies, vasculitis, myositis, serositis, nephritis, NP-SLE https://buff.ly/D5fXJdY 5. Predictors of Calcinosis Cutis in Systemic Sclerosis 6. AFFINITY Study - Combination Biologic Therapy in PsA A pilot trial assessed the efficacy and safety of the guselkumab+golimumab (COMBO) combination versus GUS monotherapy in active PsA (failing a prior tumor necrosis factor inhibitor (TNFi-IR) and showed superiority in ACR 50 https://t.co/f2CB8FnZMB 7. AAD 2026 Annual Mtg presents new data on another TYK2 inhibitor. In 2 phase 3 RCTs (ONWARD1 ONWARD2) envudeucitinib was superior to placebo & apremilast in 1700 plaque psoriasis pts https://t.co/DPlzDw5m7N 8. Among 1074 #PsA tested annually, RF positivity was found in 16.1% overall (5.1% RF+ at baseline). RF+ rediced odds of MDA (OR 0.53) w/ incr risk of bDMARD discontinuation (OR 2.65) https://buff.ly/BsM7NKQ 9. The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis - Review 10. Ixekizumab With Tirzepatide Efficacy in Obese Psoriatic Arthritis 11. Brepocitinib in Dermatomyositis
Dr. Jack Cush follows the money and all the news that fits the Rheumatology Gab for this past week.
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Dr. Jack Cush reviews the news and journal reports from RheumNow.com this week - including his top four favorite subjects.
Dr. Jack Cush reviews the news and major articles from this week, including FDA safety warnings, reports from AAD, PsA trials.
© 2020-2026 Ivy Podcast Discovery LLC
